Mustang Bio, Inc. (NASDAQ:MBIO) Sees Significant Growth in Short Interest

Mustang Bio, Inc. (NASDAQ:MBIO) saw a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 220,214 shares, an increase of 405.2% from the January 29th total of 43,589 shares. Currently, 3.1% of the company’s shares are sold short. Based on an average daily trading volume, of 771,653 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 771,653 shares, the short-interest ratio is currently 0.3 days. Currently, 3.1% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mustang Bio stock. DRW Securities LLC acquired a new position in shares of Mustang Bio, Inc. (NASDAQ:MBIO) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned 1.01% of Mustang Bio at the end of the most recent reporting period. 9.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mustang Bio in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Mustang Bio presently has an average rating of “Sell”.

Mustang Bio Price Performance

NASDAQ:MBIO traded down $0.02 during mid-day trading on Friday, hitting $1.01. The company’s stock had a trading volume of 32,332 shares, compared to its average volume of 430,083. The business’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.29. The stock has a market cap of $7.37 million, a price-to-earnings ratio of -3.26 and a beta of 2.14. Mustang Bio has a 1 year low of $0.53 and a 1 year high of $7.00.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.